NO20065112L - Kinolinon-karboksamidforbindelser som 5-HT4 receptoragonister - Google Patents

Kinolinon-karboksamidforbindelser som 5-HT4 receptoragonister

Info

Publication number
NO20065112L
NO20065112L NO20065112A NO20065112A NO20065112L NO 20065112 L NO20065112 L NO 20065112L NO 20065112 A NO20065112 A NO 20065112A NO 20065112 A NO20065112 A NO 20065112A NO 20065112 L NO20065112 L NO 20065112L
Authority
NO
Norway
Prior art keywords
alkyl
compounds
hydrogen
receptor agonists
carboxamide compounds
Prior art date
Application number
NO20065112A
Other languages
English (en)
Other versions
NO337126B1 (no
Inventor
Paul Ross Fatheree
Daniel Marquess
Seok-Ki Choi
Adam A Goldblum
Derek S Turner
Daniel D Long
Daniel Genov
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of NO20065112L publication Critical patent/NO20065112L/no
Publication of NO337126B1 publication Critical patent/NO337126B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

2006 -12- 0 8 Det tilveiebringes nye kinolinonkarboksamid-5-HT4 receptoragonistforbindelser med formel (I). Det tilveiebringes også farmasøytiske preparater omfattende slike forbindelser, anvendelsen av slike forbindelser for å behandle sykdommer assosiert med 5-HT4 receptoraktivitet, og også prosesser og mellomprodukter som er brukbare for fremstilling av slike forbindelser. I den angitte formel (I) er R' hydrogen, halo, hydroksy, C1-4 alkyl eller C1-4 alkoksy; R2 er C3-4 alkyl eller C3-6 cykloalkyl; R3 er hydrogen eller C1-3 alkyl; R4 er -S (O)2 R6 eller -C(O)R 7; R5 er hydrogen, C1-3 alkyl, C2-3 alkyl substituert med -OH eller Cl -3 alkoksy, eller -CH2-pyridyl; R6 er C1-3 alkyl; eller R5 og R6 sammen danner C3-4 alkylenyl; og R7 er hydrogen, C1-3 alkyl eller pyridyl; eller farmasøytisk akseptable salter eller solvater eller stereoisomerer derav.
NO20065112A 2004-04-07 2006-11-06 Kinolinon-karboksamidforbindelser som 5-HT4 receptoragonister NO337126B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56007604P 2004-04-07 2004-04-07
PCT/US2005/011393 WO2005100350A1 (en) 2004-04-07 2005-04-06 Quinolinone-carboxamide compounds as 5-ht4 receptor agonists

Publications (2)

Publication Number Publication Date
NO20065112L true NO20065112L (no) 2006-12-08
NO337126B1 NO337126B1 (no) 2016-01-25

Family

ID=34964334

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065112A NO337126B1 (no) 2004-04-07 2006-11-06 Kinolinon-karboksamidforbindelser som 5-HT4 receptoragonister

Country Status (29)

Country Link
US (9) US7375114B2 (no)
EP (1) EP1735304B1 (no)
JP (2) JP4944012B2 (no)
KR (1) KR101167296B1 (no)
CN (1) CN100569771C (no)
AR (1) AR050407A1 (no)
AT (1) ATE420088T1 (no)
AU (1) AU2005233560B2 (no)
BR (1) BRPI0509761B8 (no)
CA (1) CA2561558C (no)
CY (1) CY1108908T1 (no)
DE (1) DE602005012249D1 (no)
DK (1) DK1735304T3 (no)
ES (1) ES2320907T3 (no)
HK (1) HK1099019A1 (no)
HR (1) HRP20090162T1 (no)
IL (1) IL178086A (no)
MA (1) MA28559B1 (no)
MX (1) MXPA06011398A (no)
MY (1) MY155036A (no)
NO (1) NO337126B1 (no)
NZ (1) NZ549941A (no)
PL (1) PL1735304T3 (no)
PT (1) PT1735304E (no)
RU (1) RU2394033C2 (no)
SI (1) SI1735304T1 (no)
TW (1) TWI351282B (no)
WO (1) WO2005100350A1 (no)
ZA (1) ZA200608363B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1486102A (en) * 2000-11-07 2002-05-21 Immunovaccine Technologies Inc Vaccines with enhanced immune response and methods for their preparation
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
JP5086091B2 (ja) * 2004-11-05 2012-11-28 セラヴァンス， インコーポレーテッド ５−ｈｔ４受容体アゴニスト化合物
DE602005014566D1 (de) * 2004-11-05 2009-07-02 Theravance Inc Chinolinon-carboxamid-verbindungen
CN101080406A (zh) * 2004-12-22 2007-11-28 施万制药 吲唑－甲酰胺化合物
EP1871772B1 (en) * 2005-03-02 2014-09-10 Theravance, Inc. Quinolinone compounds as 5-ht4 receptor agonists
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
EP1902053B1 (en) * 2005-06-07 2011-01-12 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists
MY143574A (en) * 2005-11-22 2011-05-31 Theravance Inc Carbamate compounds as 5-ht4 receptor agonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
JP5237121B2 (ja) * 2006-02-16 2013-07-17 セラヴァンス， インコーポレーテッド ５−ｈｔ４受容体アゴニスト化合物に対する中間体を調製するためのプロセス
JP2010527357A (ja) * 2007-05-17 2010-08-12 セラヴァンス， インコーポレーテッド 腸の前処置のための運動促進剤
TWI415850B (zh) 2007-07-20 2013-11-21 Theravance Inc 製備ｍｕ類鴉片受體拮抗劑之中間物的方法
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
PT2419104T (pt) * 2009-04-13 2018-01-31 Theravance Biopharma R&D Ip Llc Combinações de agonistas do recetor 5-ht4 e inibidores da acetilcolinesterase para o tratamento de distúrbios cognitivos
US8598204B2 (en) * 2009-09-14 2013-12-03 Suven Life Sciences Limited 1,2-dihydro-2-oxoquinoline compounds as 5-HT4 receptor ligands
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
US20130296358A1 (en) 2012-05-03 2013-11-07 Ameet Vijay Ambarkhane 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
JP7431721B2 (ja) * 2017-07-31 2024-02-15 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ベルセトラグを用いて胃不全麻痺の症状を治療する方法
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
WO2019077631A1 (en) 2017-10-18 2019-04-25 Jubilant Biosys Limited IMIDAZO-PYRIDINE COMPOUNDS FOR USE AS PAD INHIBITORS
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
BR112020010322A2 (pt) 2017-11-24 2020-11-17 Jubilant Episcribe Llc composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
WO2019175897A1 (en) 2018-03-13 2019-09-19 Jubilant Biosys Limited Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
WO2023135508A1 (en) 2022-01-11 2023-07-20 Suven Life Sciences Limited PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS
WO2024061960A1 (en) 2022-09-20 2024-03-28 Alfasigma S.P.A. Velusetrag for use in the treatment of chronic intestinal pseudo-obstruction (cipo)

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321378A (en) 1979-01-16 1982-03-23 Delalande S.A. 8-(5-Pyrimidinecarboxamide)nor-tropane derivatives
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8527052D0 (en) 1985-11-02 1985-12-04 Beecham Group Plc Compounds
NL8701682A (nl) 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
US4948803A (en) 1986-11-21 1990-08-14 Glaxo Group Limited Medicaments for treatment on prevention of withdrawal syndrome
GB8701022D0 (en) 1987-01-19 1987-02-18 Beecham Group Plc Treatment
US5223511A (en) 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
IT1231413B (it) 1987-09-23 1991-12-04 Angeli Inst Spa Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht
IT1226389B (it) 1988-07-12 1991-01-15 Angeli Inst Spa Nuovi derivati ammidinici e guanidinici
NZ230068A (en) 1988-07-29 1991-07-26 Dainippon Pharmaceutical Co Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
EP0410509A1 (en) 1989-07-25 1991-01-30 Duphar International Research B.V New substituted 1H-indazole-3-carboxamides
JPH045289A (ja) 1990-04-24 1992-01-09 Hokuriku Seiyaku Co Ltd アミド化合物
JP3122671B2 (ja) 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
HU211081B (en) 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
DE69113284T2 (de) 1990-12-28 1996-02-22 Kyowa Hakko Kogyo Kk Chinolinderivat.
NZ243993A (en) 1991-08-20 1994-10-26 Smithkline Beecham Plc Pharmaceutical compositions having 5-ht4 receptor antagonist activity and selected compounds having such activity
WO1993005040A1 (en) 1991-09-12 1993-03-18 Smithkline Beecham Plc Azabicyclic compounds as 5-ht4 receptor antagonists
MX9305947A (es) 1992-09-29 1994-06-30 Smithkline Beecham Plc Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
AU5161593A (en) 1992-11-20 1994-06-22 Taisho Pharmaceutical Co., Ltd. Heterocyclic compound
TW251287B (no) 1993-04-30 1995-07-11 Nissei Co Ltd
GB9310582D0 (en) 1993-05-22 1993-07-07 Smithkline Beecham Plc Pharmaceuticals
CA2184366A1 (en) 1994-02-28 1995-08-31 Yutaka Ohuchi Heterocyclic compound
US5864039A (en) 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
GB9406857D0 (en) 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
JP3829879B2 (ja) * 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
JP3796766B2 (ja) * 1994-05-18 2006-07-12 大正製薬株式会社 アルキル置換キノリンカルボン酸誘導体
CA2160420A1 (en) 1994-10-20 1996-04-21 Haruhiko Kikuchi 5-ht4 receptor agonists
JP3829880B2 (ja) 1994-12-27 2006-10-04 大正製薬株式会社 化学中間体
US5612339A (en) * 1995-01-17 1997-03-18 Trustees Of The University Of Pennsylvania 2-Hydroxy-3-aminopropylsulfonamides
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
US5654320A (en) 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
US5945434A (en) 1995-05-31 1999-08-31 Nisshin Flour Milling Co., Ltd. Indazole derivatives having monocyclic amine
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
ES2109190B1 (es) 1996-03-22 1998-07-01 Univ Madrid Complutense Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht
IT1291569B1 (it) 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US6069152A (en) 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
US5914405A (en) 1997-10-07 1999-06-22 Eli Lilly And Company Process for preparing 3-substituted indazoles
FR2769915B1 (fr) 1997-10-21 2000-10-13 Synthelabo Derives d'indazole tricycliques, leur preparation et leur application en therapeutique
IT1298271B1 (it) 1998-02-18 1999-12-20 Boehringer Ingelheim Italia Esteri ed ammidi dell'acido 2-oxo-2,3-diidro-benzimidazol-1- carbossilico
CN1118452C (zh) 1998-04-28 2003-08-20 大日本制药株式会社 1－[(1－取代－4－哌啶基)甲基]－4－哌啶衍生物、其生产方法、含有该化合物的药物组合物和这些化合物的中间体
AU758807B2 (en) 1998-09-10 2003-03-27 F. Hoffmann-La Roche Ag Dihydrobenzodioxine carboxamide and ketone derivatives as 5-HT4 receptor antagonists
TW570920B (en) 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
FR2792318B1 (fr) 1999-04-16 2001-06-15 Synthelabo Derives d'indazole, leur preparation et leur application en therapeutique
CN1461216A (zh) 1999-04-28 2003-12-10 呼吸器有限公司 用作治疗有关支气管收缩的机能障碍的药物的化合物
ES2154605B1 (es) 1999-09-14 2001-11-16 Univ Madrid Complutense Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
IT1313625B1 (it) 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
AU2002212888A1 (en) * 2000-11-01 2002-05-15 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US6624162B2 (en) 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
CA2499494A1 (en) 2002-09-20 2004-04-01 Pfizer Inc. N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
DOP2003000703A (es) 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
CA2523077A1 (en) 2003-04-21 2004-11-04 Pfizer Inc. Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
PL1641783T3 (pl) 2003-06-19 2012-08-31 Janssen Pharmaceutica Nv 4-(aminometylo)-piperydyno-benzamidy podstawione aminosulfonylem jako antagoniści 5HT₄
JO2478B1 (en) 2003-06-19 2009-01-20 جانسين فارماسوتيكا ان. في. (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
EA009457B1 (ru) * 2003-09-03 2007-12-28 Пфайзер Инк. Бензимидазолоновые соединения, обладающие агонистической активностью в отношении 5-нтрецепторов
ES2338882T3 (es) 2003-11-24 2010-05-13 Pfizer, Inc. Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4.
WO2005073222A1 (en) 2004-01-29 2005-08-11 Pfizer Japan, Inc. 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-ht4 receptor agonistic activity
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
JP5086091B2 (ja) 2004-11-05 2012-11-28 セラヴァンス， インコーポレーテッド ５−ｈｔ４受容体アゴニスト化合物
DE602005014566D1 (de) * 2004-11-05 2009-07-02 Theravance Inc Chinolinon-carboxamid-verbindungen
CN101080406A (zh) 2004-12-22 2007-11-28 施万制药 吲唑－甲酰胺化合物
EP1871772B1 (en) 2005-03-02 2014-09-10 Theravance, Inc. Quinolinone compounds as 5-ht4 receptor agonists
TWI377206B (en) 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
EP1902053B1 (en) 2005-06-07 2011-01-12 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
KR101167296B1 (ko) 2012-07-23
US8575192B2 (en) 2013-11-05
US20070270457A1 (en) 2007-11-22
HRP20090162T1 (en) 2009-05-31
ATE420088T1 (de) 2009-01-15
JP4944012B2 (ja) 2012-05-30
EP1735304A1 (en) 2006-12-27
PL1735304T3 (pl) 2009-06-30
CN1946719A (zh) 2007-04-11
US7592355B2 (en) 2009-09-22
US20100311979A1 (en) 2010-12-09
US9873692B2 (en) 2018-01-23
BRPI0509761B1 (pt) 2018-07-31
JP2008174569A (ja) 2008-07-31
CY1108908T1 (el) 2014-07-02
ES2320907T3 (es) 2009-05-29
US8163920B2 (en) 2012-04-24
CA2561558C (en) 2013-06-18
TW200536540A (en) 2005-11-16
AU2005233560B2 (en) 2012-04-05
ZA200608363B (en) 2008-05-25
RU2006139053A (ru) 2008-05-20
NO337126B1 (no) 2016-01-25
HK1099019A1 (en) 2007-08-03
MXPA06011398A (es) 2006-12-20
BRPI0509761B8 (pt) 2021-05-25
US20080176895A1 (en) 2008-07-24
BRPI0509761A (pt) 2007-10-16
US20150291580A1 (en) 2015-10-15
US7375114B2 (en) 2008-05-20
KR20070015423A (ko) 2007-02-02
TWI351282B (en) 2011-11-01
US7763637B2 (en) 2010-07-27
EP1735304B1 (en) 2009-01-07
US20140163063A1 (en) 2014-06-12
CA2561558A1 (en) 2005-10-27
AU2005233560A1 (en) 2005-10-27
WO2005100350A1 (en) 2005-10-27
DK1735304T3 (da) 2009-04-20
IL178086A (en) 2011-09-27
MA28559B1 (fr) 2007-04-03
US8962653B2 (en) 2015-02-24
US20050228014A1 (en) 2005-10-13
WO2005100350A8 (en) 2006-12-07
US9353106B2 (en) 2016-05-31
DE602005012249D1 (de) 2009-02-26
US20160376264A1 (en) 2016-12-29
RU2394033C2 (ru) 2010-07-10
SI1735304T1 (sl) 2009-06-30
IL178086A0 (en) 2006-12-31
PT1735304E (pt) 2009-03-27
US20120264779A1 (en) 2012-10-18
US9630960B2 (en) 2017-04-25
CN100569771C (zh) 2009-12-16
US20170334901A1 (en) 2017-11-23
MY155036A (en) 2015-08-28
AR050407A1 (es) 2006-10-25
NZ549941A (en) 2010-09-30
JP2007532546A (ja) 2007-11-15

Similar Documents

Publication Publication Date Title
NO20065112L (no) Kinolinon-karboksamidforbindelser som 5-HT4 receptoragonister
CA2898650C (en) Quinoline and quinoxaline amides as modulators of sodium channels
ES2654393T3 (es) Sulfonamidas como moduladores de los canales de sodio
RU2662223C2 (ru) Пиридонамиды в качестве модуляторов натриевых каналов
US20220110923A1 (en) Esters and carbamates as modulators of sodium channels
JP5301469B2 (ja) Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体
US20230062053A1 (en) Carboxamides as modulators of sodium channels
JP2019112459A (ja) 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター
JP2016175940A (ja) ナトリウムチャネル遮断剤としてのピリミジン
US20140221435A1 (en) Amides as modulators of sodium channels
MX2008016492A (es) Derivados de urea de tropano, su preparacion y su aplicacion terapeutica.
JP2015517495A (ja) ＲＯＲγ活性を阻害し疾患を治療するための二環式スルホン化合物
AU5539694A (en) Catechol diethers as selective PDE-IV inhibitors
KR20140078626A (ko) 카텝신 ｃ의 치환된 ｎ­［１­시아노­２­（페닐）에틸］­２­아자바이사이클로［２.２.１］헵탄­３­카복스아미드 억제제
RS53627B1 (en) N- (3-Amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
NO20055977L (no) Nye benzimidazolderivater
WO2006091862A2 (en) Cytokine inhibitors and their use in therapy
BRPI0619126A2 (pt) derivados espirocìclicos, composição farmacêutica e usos dos mesmos
MX2012015170A (es) Derivados de 3-amino-5,6-dihidro-1h-pirazin-2-ona utiles para el tratamiento de la enfermedad de alzheimer y otras formas de demencia.
KR102293386B1 (ko) 신규한 (시아노-디메틸-메틸)-이속사졸 및 -[1,3,4]티아디아졸
US20100216823A1 (en) Spirocyclic Derivatives
JP2016515110A (ja) カテプシンｃの置換２−アザ−ビシクロ［２．２．２］オクタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
NO20074622L (no) Metabolitter for NK-1 antagonister for brekninger
NO20063562L (no) Fusjonerte heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
TR200200969T2 (tr) Karbonilamino türevlerinin CNS bozukluklarına karşı kullanılması

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: THERAVANCE BIOPHARMA R&D IP, US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: THERAVANCE BIOPHARMA R&D IP, US

MM1K Lapsed by not paying the annual fees